Literature DB >> 34741235

Is the regulation by miRNAs of NTPDase1 and ecto-5'-nucleotidase genes involved with the different profiles of breast cancer subtypes?

Fernanda Cardoso da Silva1, Angelo Borges de Melo Neto2, Christina Aparecida Martins1, Thaís Cunha de Sousa Cardoso2, Matheus de Souza Gomes2, Thaise Gonçalves de Araújo3, Cristina Ribas Fürstenau4.   

Abstract

Breast cancer (BC) is a public health problem worldwide, causing suffering and premature death among women. As a heterogeneous disease, BC-specific diagnosis and treatment are challenging. Ectonucleotidases are related to tumor development and their expression may vary among BC. miRNAs may participate in epigenetic events and may regulate ectonucleotidases in BC. This study aimed to evaluate the expression of ectonucleotidases according to BC subtypes and to predict if there is post-transcriptional regulation of them by miRNAs. MCF 10A (non-tumorigenic), MCF7 (luminal BC), and MDA-MB-231 (triple-negative BC - TNBC) breast cell lines were used and ENTPD1 (the gene encoding for NTPDase1) and NT5E (the gene encoding for ecto-5'-nucleotidase) gene expression was determined. Interestingly, the expression of ENTPD1 was only observed in MCF7 and NT5E was lower in MCF7 compared to MDA-MB-231 cell line. ATP, ADP, and AMP hydrolysis were observed on the surface of all cell lines, being higher in MDA-MB-231. Like qPCR, the activity of AMP hydrolysis was also lower in the MCF7 cells, which may represent a striking feature of this BC subtype. In silico analyses confirmed that the miRNAs miR-101-3p, miR-141-3p, and miR-340-5p were higher expressed in MCF7 cells and targeted NT5E mRNA. Altogether, data suggest that the regulation of NT5E by miRNAs in MCF7 lineage may direct the molecular profile of luminal BC. Thus, we suggest that the roles of ecto-5'-nucleotidase and the aforementioned miRNAs must be unraveled in TNBC to be possibly defined as diagnostic and therapeutic targets.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Adenosine; Breast cancer; CD73; miR-101-3p; miR-141-3p; miR340-5p

Mesh:

Substances:

Year:  2021        PMID: 34741235      PMCID: PMC8850496          DOI: 10.1007/s11302-021-09824-4

Source DB:  PubMed          Journal:  Purinergic Signal        ISSN: 1573-9538            Impact factor:   3.765


  63 in total

1.  Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells.

Authors:  Tissa T Manavalan; Yun Teng; Savitri N Appana; Susmita Datta; Theodore S Kalbfleisch; Yong Li; Carolyn M Klinge
Journal:  Cancer Lett       Date:  2011-09-10       Impact factor: 8.679

2.  [miR-101 inhibits the proliferation and migration of breast cancer cells via downregulating the expression of DNA methyltransferase 3a].

Authors:  Jian Liu; Yamei Pang; Huangzhen Wang; Yanbo Li; Xin Sun; Fei Xu; Hong Ren; Dapeng Liu
Journal:  Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi       Date:  2016-03

3.  A direct colorimetric assay for Ca2+ -stimulated ATPase activity.

Authors:  K M Chan; D Delfert; K D Junger
Journal:  Anal Biochem       Date:  1986-09       Impact factor: 3.365

4.  CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer.

Authors:  Sherene Loi; Sandra Pommey; Benjamin Haibe-Kains; Paul A Beavis; Phillip K Darcy; Mark J Smyth; John Stagg
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-17       Impact factor: 11.205

5.  Characterization of circulating microparticle-associated CD39 family ecto-nucleotidases in human plasma.

Authors:  Z Gordon Jiang; Yan Wu; Eva Csizmadia; Linda Feldbrügge; Keiichi Enjyoji; John Tigges; Vasilis Toxavidis; Holger Stephan; Christa E Müller; Christina E Müller; C James McKnight; Alan Moss; Simon C Robson
Journal:  Purinergic Signal       Date:  2014-08-28       Impact factor: 3.765

6.  Enhanced migration of breast and lung cancer cells deficient for cN-II and CD73 via COX-2/PGE2/AKT axis regulation.

Authors:  Octavia Cadassou; Muhammad-Zawwad Raza; Christelle Machon; Laura Gudefin; Célia Armanet; Kamel Chettab; Jérôme Guitton; Maria Grazia Tozzi; Charles Dumontet; Emeline Cros-Perrial; Lars Petter Jordheim
Journal:  Cell Oncol (Dordr)       Date:  2020-09-24       Impact factor: 6.730

Review 7.  NTPDase5/PCPH as a new target in highly aggressive tumors: a systematic review.

Authors:  Paula Andreghetto Bracco; Ana Paula Santin Bertoni; Márcia Rosângela Wink
Journal:  Biomed Res Int       Date:  2014-06-23       Impact factor: 3.411

Review 8.  Extracellular purines, purinergic receptors and tumor growth.

Authors:  F Di Virgilio; E Adinolfi
Journal:  Oncogene       Date:  2016-06-20       Impact factor: 9.867

9.  Tiamulin inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of CD73.

Authors:  Xu Yang; Shimin Pei; Huanan Wang; Yipeng Jin; Fang Yu; Bin Zhou; Hong Zhang; Di Zhang; Degui Lin
Journal:  BMC Cancer       Date:  2017-04-11       Impact factor: 4.430

Review 10.  Targeting the purinergic pathway in breast cancer and its therapeutic applications.

Authors:  Julia Beatrice de Araújo; Vanessa Vitória Kerkhoff; Sarah Franco Vieira de Oliveira Maciel; Débora Tavares de Resende E Silva
Journal:  Purinergic Signal       Date:  2021-02-12       Impact factor: 3.765

View more
  1 in total

Review 1.  Scrutinizing the Therapeutic Promise of Purinergic Receptors Targeting Depression.

Authors:  Priyanshi Sikka; Tapan Behl; Parteek Chandel; Aayush Sehgal; Sukhbir Singh; Hafiz A Makeen; Mohammed Albratty; Hassan A Alhazmi; Abdulkarim M Meraya
Journal:  Neurotox Res       Date:  2022-08-05       Impact factor: 3.978

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.